Inhibikase Therapeutics Inc
Research Inhibikase Therapeutics Inc (IKT) on Bullrun: market cap USD 254.82M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIKT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 254.82M
- Financial periodFY2025
- Net income-USD 48.26M
- Free cash flow-USD 27.80M
Valuation Snapshot
latest market cap is USD 254.82M.
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Frequently asked questions
What is Inhibikase Therapeutics Inc's market cap?
Inhibikase Therapeutics Inc's market capitalization is USD 254.82M.
What does Inhibikase Therapeutics Inc do?
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular...